Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
150.1 USD | +1.54% | +0.29% | -21.60% |
Financials (USD)
Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 18.98B |
---|---|---|---|---|---|
Net income 2024 * | -451M | Net income 2025 * | -257M | EV / Sales 2024 * | 9.47 x |
Net cash position 2024 * | 1.26B | Net cash position 2025 * | 475M | EV / Sales 2025 * | 8.19 x |
P/E ratio 2024 * |
-42.5
x | P/E ratio 2025 * |
-80.6
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | +1.54% | ||
1 week | +0.29% | ||
Current month | +4.24% | ||
1 month | +4.71% | ||
3 months | -3.33% | ||
6 months | -7.00% | ||
Current year | -21.60% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | 0.00% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 150.1 | +1.56% | 510,344 |
24-05-24 | 147.8 | -1.08% | 506,806 |
24-05-23 | 149.4 | -1.01% | 500,527 |
24-05-22 | 150.9 | +0.86% | 350,723 |
24-05-21 | 149.6 | -0.41% | 448,620 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.60% | 18.98B | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.57% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B | |
-9.26% | 11.05B |
- Stock Market
- Equities
- ALNY Stock